Introducing Our Guide to Clinical Evaluation Video Series: Building Strong Submissions Under MDR

Paul Hercock

Clinical evaluation is one of the most critical and most challenging aspects of achieving CE marking under the EU Medical Device Regulation (MDR).

At Mantra Systems, we find that it is also the single most common reason for regulatory submissions to fail. Yet, with the right approach, it becomes not just a compliance requirement but an opportunity to demonstrate the safety, performance, and clinical value of a medical device.

That’s why we’re launching our new Guide to Clinical Evaluation Video Series - a step-by-step guide to navigating the process with confidence. Across five episodes, we’ll break down the principles of clinical evaluation, highlight common pitfalls, and share strategies that have helped us deliver more than 300 MDR clinical evaluations with a 100% success rate.

What You’ll Learn in This Series

We’ll walk through each of the key building blocks of clinical evaluation: a

  1. What is clinical evaluation?
  2. Clinical evaluation in context
  3. The State-of-the-Art (SOTA) review – core of a successful submission
  4. The CEP and CER
  5. Clinical evaluation pitfalls and useful resources

Our aim is simple: to make the clinical evaluation process clearer, more accessible, and more effective for regulatory teams and manufacturers alike.

Episode One: What is Clinical Evaluation?

In the first video of the series, we begin with the fundamentals: what a clinical evaluation is and what the major components are.

At its core, a clinical evaluation has four main objectives:

  • To demonstrate that a device is suitable for its intended purpose.
  • To demonstrate conformity with the relevant General Safety and Performance Requirements (GSPRs).
  • To demonstrate non-inferiority to safety and performance objectives, derived from the SOTA review.
  • To demonstrate the acceptability of the device’s benefit-risk ratio.

Achieving these objectives requires both technical precision and sound scientific judgment. Errors here are costly, often leading to prolonged review cycles or rejection by a Notified Body.

At the heart of achieving these objectives are three essential components of any successful clinical evaluation:

Together, these three elements form the backbone of a robust clinical evaluation. In this series, we’ll explore each in detail, showing not only how they interconnect, but also how to avoid the common pitfalls that often derail submissions.

A Proven Framework for Success

At Mantra Systems, we know what success looks like. Our approach to clinical evaluation is built on experience: over 300 successful evaluations conducted under MDR. This track record reflects not just regulatory knowledge, but also a deep commitment to patient safety, clinical relevance, and quality of evidence.

Through this series, we’ll share that expertise with you, helping you avoid the pitfalls we see most often and giving you a clear pathway to stronger, more resilient submissions.

Subscribe to our newsletter to keep up with the full five-part series on mastering MDR clinical evaluation.

Will your CER stand up to Notified Body scrutiny?

Get your CER critically reviewed by one of our expert medical writers. Our Clinical Evaluation pre-submission check identifies gaps, highlights risks, and provides actionable guidance to maximise your submission success.

Related articles

  1. A process flow leading to a cybersecurity evidence pack

    EU MDR, FDA 510(k) and DTAC Cybersecurity Nonconformities: How to Recover

    This guest article shows how these cybersecurity nonconformities happen, what recovery actually involves, and what to build so you don't go back.

    Neil Richardson Neil Richardson Co-Founder of Cyber Alchemy
  2. Turning blocks from crosses to ticks

    How to handle non-conformities and get back on track

    A practical guide to understanding why non-conformities happen, the most common issues in medical device submissions, and how to resolve them efficiently to get you back on track.

    Dr Will Brambley Dr Will Brambley Lead Medical Writer
  3. US and EU flags on poles alongside each other.

    Clinical Evidence under EU MDR: Leveraging FDA Clinical Data to Streamline EU MDR Compliance

    FDA approval alone is not sufficient for European market access - a theme we explore futher in this article and the accompanying webinar.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  4. 3 people in an office in front of a whiteboard with the words 'Medical Device Market Entry Strategy' written above a world map.

    EU MDR & NHS DTAC Cybersecurity Requirements for UK Market Entry

    This guest article shows you how to build cybersecurity evidence for the EU MDR and NHS DTAC.

    Luke Hill Luke Hill Co-Founder of Cyber Alchemy
  5. An illustration showing a GPS-driven navigation route superimposed upon someone using a laptop.

    Where to Launch First? A MedTech Founder's Regulatory Roadmap to the EU, UK and US

    All three markets operate under different regulatory systems and place different demands on manufacturers.

    Ronghe Xu Ronghe Xu Regulatory Medical Writer & Strategic BD Lead China
  6. A woman uses an inhaler.

    Navigating EU MDR Article 117: A Practical Guide to Drug-Device Combination Product Submissions

    Implementation of the EU MDR 2017/745 has brought significant changes.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  7. NHS CEP logo.

    Mantra Systems becomes an official Programme Partner of the NHS Clinical Entrepreneur Programme

    We're proud to join a this initiative supporting healthcare workers and patients to develop innovative solutions for the NHS.

    Paul Hercock Paul Hercock CEO & Founder
  8. Collage art showing a pair of binoculars, an analogy for surveillance.

    How EU MDR Post Market Surveillance differs from FDA post-market expectations

    We compare manufacturer-specific post-market obligations across both regulatory systems.

    Dr Gayle Buchel Dr Gayle Buchel Chief Medical Writer
  9. An arrow arcs from the US over to Europe.

    How EU device classification differs from the US - Are you Prepared?

    Did you know an FDA Class II medical device could be immediately considered as a high-risk Class III device under European Union regulations?

    Gabriela Cardoso Gabriela Cardoso Regulatory Medical Writer
  10. A magnifying glass inspecting a number of wooden cubes with question marks upon them laid upon a blue table. The wooden cube under the magnifying glass has a lightbulb painted on it.

    Fixing the MDR and IVDR? The Commission’s Proposed Amendments and What They Mean for Manufacturers

    Exploring the key elements of this proposal.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  11. An illustration showing a business woman pole-vaulting across a ravine.

    Eliminating the Top 5 Notified Body Gaps in Clinical Evaluation Through Pre-Submission Review

    From insufficient clinical evidence to Post-Market issues - we guide you past common NB deficiencies.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  12. Two arms point at a sign and hold a question mark, in an abstract pop-art style.

    Regulatory Reset? The EU’s Proposed Changes to MDR and IVDR Explained

    Changes published in December 2025 aim to streamline EU medical device and in vitro diagnostics. We explain who is impacted and how.

    Dr Gayle Buchel Dr Gayle Buchel Chief Medical Writer

More articles

Need help producing compliant CEPs & CERs? We are offering FREE CEPs to 5 qualifying applicants per week

Get your free CEP